Basic & Clinical Medicine ›› 2022, Vol. 42 ›› Issue (1): 159-162.

Previous Articles     Next Articles

Research progress on IL-6/JAK/STAT3 in the development and treatment of prostate cancer

  

  • Received:2021-04-15 Revised:2021-08-07 Online:2022-01-05 Published:2022-01-05
  • Contact: Wu Wu JingJing E-mail:wujingkm126@176.com

Abstract: IL-6/JAK/STAT3 is one of the most significant signaling pathways activated by IL-6.IL-6 and p-STAT3 are highly expressed in prostate cancer (PCa) tissues and metastatic tumors, and play a key role in inducing the occurrence of prostate cancer, promoting the proliferation, invasion and metastasis of tumor cells, and participating in castration resistance and tumor drug resistance of PCa through activation of AR.The multiple roles of IL-6/JAK/STAT3 and its activated downstream factors in tumor progression provide a good basis for the development of chemotherapy drugs. Currently, many targeted inhibitors have been proved to be effective in inhibiting tumor progression, and more effective drugs are expected to be developed.

Key words: Prostate cancer, castration-resistant prostate cancer, Interleukin 6, STAT3